Preclinical evaluation of teleglenastat (CB-839) in prostate cancer. This is an ASCO Meeting Abstract from the 2023 ASCO Genitourinary Cancers Symposium. This abstract does not include a full text ...
Prostate cancer (PCa) is the second most commonly diagnosed cancer and the fifth leading cause of cancer-related mortality for males worldwide [1]. In the USA, PCa is the malignancy with the highest ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results